Sugi Predict

Sugi Predict / Compounds / SCHEMBL3600256

SCHEMBL3600256

SCHEMBL3600256

CN(C)S(=O)(=O)N1CCCCC1

nearest known ligand 0.81

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.81
▸ ALDH1A1 P00352 3/20 0.50
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ POLB P06746 2/20 0.48
▸ KMT2A Q03164 4/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ HTT P42858 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9987759 1.00 GAA (0.81) GAAALDH1A1CA1CA2POLB
Hydrochloric Acid SCHEMBL27685977 0.97 GAA (0.77) GAAALDH1A1CA1CA2POLB
SCHEMBL3634814 0.97 GAA (0.85) GAAALDH1A1CA1CA2POLB
SCHEMBL3630393 0.97 GAA (0.85) GAAALDH1A1CA1CA2POLB
SCHEMBL15283000 0.92 GAA (0.95) GAAALDH1A1KMT2ATSHRMEN1
SCHEMBL11142722 0.86 — —
SCHEMBL13902800 0.80 GAA (0.79) GAAALDH1A1KMT2AMEN1HTT
SCHEMBL28551255 0.78 GAA (0.63) GAAALDH1A1KMT2ATSHRMEN1
SCHEMBL8978099 0.77 GAA (0.70) GAAALDH1A1POLBKMT2AMEN1
SCHEMBL1377365 0.77 GAA (0.62) GAAALDH1A1KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114585619-B Alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2024-09-27 — — CN claimed
CN-116162084-A Pyran derivatives as CYP11A1 inhibitors 奥赖恩公司 2023-05-26 — — CN claimed
CN-110139861-B Pyran derivatives as CYP11A1 (cytochrome P450 monooxygenase 11A 1) inhibitors 奥赖恩公司 2022-12-30 — — CN claimed
CN-114585619-A alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-06-03 — — CN claimed
CN-110072864-B TDO2 inhibitors 基因泰克公司 2022-05-27 — — CN claimed
WO-2021096314-A1 NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF 가천대학교 산학협력단 2021-05-20 — — WO claimed
EP-3394068-A1 TDO2 INHIBITORS Genentech, Inc. (US) 2018-10-31 — — EP claimed
WO-2017107979-A1 TDO2 INHIBITORS GENENTECH, INC. (US) 2017-06-29 — — WO claimed
CN-101511429-A Indulines derivatives and gpr119 agonists SMITHKLINE BEECHAM CORP (US) 2009-08-19 — — CN claimed
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2025-08-14 — — US disclosed
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-08-05 — — US disclosed
US-12319672-B2 Alpha-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-03 — — US disclosed
CN-119462605-A CYP11A1 inhibitor and application thereof 轩竹生物科技股份有限公司 2025-02-18 — — CN disclosed
EP-3885348-B1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RES INST CHEMICAL TECH (KR) 2025-02-12 — — EP disclosed
US-20180044306-A1 1,3,4-THIADIAZOL-2-YL-BENZAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-02-15 — — US disclosed
US-20170183348-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2017-06-29 — — US disclosed
WO-2017107979-A1 TDO2 INHIBITORS GENENTECH, INC. (US) 2017-06-29 — — WO disclosed
US-8362037-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2013-01-29 — — US disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 — — US disclosed
CN-101511429-A Indulines derivatives and gpr119 agonists SMITHKLINE BEECHAM CORP (US) 2009-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 GAA 185/4885ALDH1A1 251/4885CA1 2514/4885
US-20180044306-A1 1,3,4-THIADIAZOL-2-YL-BENZAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY WNT1, CTNND1, CTNNB1 GAA 1196/4885ALDH1A1 1023/4885CA1 4884/4885
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor IRAK4, IRAK1, IRAK2 GAA 3869/4885ALDH1A1 2912/4885CA1 2727/4885
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GAA 83/4885ALDH1A1 1205/4885CA1 4332/4885
US-20170183348-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK NRAS, BRAF, KRAS GAA 3676/4885ALDH1A1 2338/4885CA1 4711/4885
US-12319672-B2 Alpha-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 GAA 201/4885ALDH1A1 134/4885CA1 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.